Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 2Withdrawn 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Ovarian Neoplasms 3Melanoma 3Carcinoma, Renal Cell 3Fallopian Tube Neoplasms 2Urogenital Neoplasms 1Triple Negative Breast Neoplasms 1Thyroid Carcinoma, Anaplastic 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1Recurrence 1Osteosarcoma 1Neoplasms 1Meningeal Neoplasms 1Kidney Neoplasms 1Histiocytoma, Malignant Fibrous 1Giant Cell Tumor of Bone 1Gastrointestinal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Squamous Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Bone Neoplasms 1

Interventions

Nivolumab 2Ipilimumab 2vedolizumab 1gallium 68 PSMA-11 1fludarabine 1cabozantinib 1aldesleukin 1abiraterone 1abemaciclib 1Therapeutics 1Specimen Handling 1Prednisone 1Prednisolone 1Magnetic Resonance Spectroscopy 1LDP-02 1Interleukin-2 1Infliximab 1Immunoglobulin G 1Geriatric Assessment 1Fulvestrant 1Exercise 1Disulfides 1Cyclophosphamide 1CTLA-4 Antigen 1CT-P13 1Biopsy 1Androgen Antagonists 1Adrenal Cortex Hormones 1(225)Ac-PSMA-617 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Urogenital Neoplasms × aldesleukin × Clear all
NCT06253520 2026-05-08

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1 Active not recruiting
210 enrolled
BreastGastrointestinalGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Gastrointestinal Neoplasms, Ovarian Neoplasms, Urogenital Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡